Jagsonpal Pharmaceuticals Beneish M-Score Historical Data
The historical data trend for Jagsonpal Pharmaceuticals's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jagsonpal Pharmaceuticals Beneish M-Score Chart
|
Jagsonpal Pharmaceuticals Annual Data
|
|
Trend |
Mar14 |
Mar15 |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
Mar23 |
| Beneish M-Score |
|
Get a 7-Day Free Trial
|
|
|
-3.32 |
-2.39 |
-3.11 |
-1.76 |
-2.97 |
|
Jagsonpal Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Beneish M-Score |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
-2.97 |
- |
- |
- |
Competitive Comparison of Jagsonpal Pharmaceuticals's Beneish M-Score
For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jagsonpal Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Jagsonpal Pharmaceuticals's Beneish M-Score falls into.
Jagsonpal Pharmaceuticals Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Jagsonpal Pharmaceuticals for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 1.2316 | + | 0.528 * 0.9731 | + | 0.404 * 0.158 | + | 0.892 * 1.0879 | + | 0.115 * 1.3717 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 0.9314 | + | 4.679 * -0.102254 | - | 0.327 * 1.025 |
| = | -2.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar23) TTM: | Last Year (Mar22) TTM: |
Total Receivables was ₹209 Mil.
Revenue was ₹2,367 Mil.
Gross Profit was ₹1,434 Mil.
Total Current Assets was ₹1,646 Mil.
Total Assets was ₹1,949 Mil.
Property, Plant and Equipment(Net PPE) was ₹243 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹12 Mil.
Selling, General, & Admin. Expense(SGA) was ₹244 Mil.
Total Current Liabilities was ₹276 Mil.
Long-Term Debt & Capital Lease Obligation was ₹52 Mil.
Net Income was ₹267 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹467 Mil.
|
Total Receivables was ₹156 Mil.
Revenue was ₹2,176 Mil.
Gross Profit was ₹1,283 Mil.
Total Current Assets was ₹1,091 Mil.
Total Assets was ₹1,642 Mil.
Property, Plant and Equipment(Net PPE) was ₹226 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹15 Mil.
Selling, General, & Admin. Expense(SGA) was ₹241 Mil.
Total Current Liabilities was ₹270 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (208.72 / 2367.14) | / | (155.77 / 2175.84) |
| = | 0.088174 | / | 0.071591 |
| | = | 1.2316 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (1283.02 / 2175.84) | / | (1434.42 / 2367.14) |
| = | 0.589667 | / | 0.605972 |
| | = | 0.9731 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (1645.59 + 242.78) / 1949.46) | / | (1 - (1090.81 + 225.73) / 1642.25) |
| = | 0.031337 | / | 0.198332 |
| | = | 0.158 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 2367.14 | / | 2175.84 |
| | = | 1.0879 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (15.26 / (15.26 + 225.73)) | / | (11.75 / (11.75 + 242.78)) |
| = | 0.063322 | / | 0.046164 |
| | = | 1.3717 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (243.72 / 2367.14) | / | (240.52 / 2175.84) |
| = | 0.10296 | / | 0.110541 |
| | = | 0.9314 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((52.47 + 275.71) / 1949.46) | / | ((0 + 269.72) / 1642.25) |
| = | 0.168344 | / | 0.164238 |
| | = | 1.025 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (267.21 - 0 | - | 466.55) | / | 1949.46 |
| | = | -0.102254 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Jagsonpal Pharmaceuticals has a M-score of -2.97 suggests that the company is unlikely to be a manipulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:JAGSNPHARM has been successfully added to your